0 citations
A Partially-Randomised Phase 3 Trial of Pretomanid, Moxifloxacin and Pyrazinamide in Combination for the Treatment of Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis
SSRN Electronic Journal2020
Citations Over Time
Conor Tweed, Genevieve H. Wills, Angela M. Crook, Evans Amukoye, Vincent M. Balanag, Bán A, Anna L. C. Bateson, Matthew C Betteridge, William Brumskine, Janice Caoili, Richard E. Chaisson, Müge Çevik, Francesca Conradie, Rodney Dawson, Angelo Del Parigi, Andreas H. Diacon, Daniel E. Everitt, Stella M. Fabiane, Robert Hunt, Nor Hadiani Ismail, Umesh Lalloo, Leandra Lombard, Cheryl Louw, Mookho Malahleha, Timothy D. McHugh, Carl M. Mendel, Francis Mhimbira, Ronellle N Moodliar, Videlis Nduba, Andrew Nunn, Issa Sabi, Modulakgotla Sebe, Raesibe AP Selepe, Suzanne Staples, Susan Swindells, C.H. van Niekerk, Ebrahim Variava, Mel Spigelman, Stephen H. Gillespie
Related Papers
- → Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis(2004)221 cited
- → Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis(2017)100 cited
- → Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis(2019)98 cited
- → Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?(2008)65 cited
- → Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis(2019)14 cited